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Abstract: Virola is the largest genus of Myristicaceae in America, comprising about 60 species of
medium-sized trees geographically spread from Mexico to southern Brazil. The plant species of this
genus have been widely used in folk medicine for the treatment of several ailments, such as rheumatic
pain, bronchial asthma, tumors in the joints, intestinal worms, halitosis, ulcers, and multiple infec-
tions, due to their pharmacological activity. This review presents an updated and comprehensive
summary of Virola species, particularly their ethnomedicinal uses, phytochemistry, and biological
activity, to support the safe medicinal use of plant extracts and provide guidance for future research.
The Virola spp.’s ethnopharmacology, including in the treatment of stomach pain and gastric ulcers,
as well as antimicrobial and tryponosomicidal activities, is attributable to the presence of a myriad of
phytoconstituents, such as flavonoids, tannins, phenolic acids, lignans, arylalkanones, and sitosterol.
Hence, such species yield potential leads or molecular scaffolds for the development of new pharma-
ceutical formulations, encouraging the elucidation of not-yet-understood action mechanisms and
ascertaining their safety for humans.
Keywords: Myristicaceae; pharmacology; phytotherapy; Virola surinamensis; Virola sebifera; resin;
essential oil; flavonoid; lignan; alkaloid
1. Introduction
Plant extracts have long been used as illness remedies in traditional medicine. Indeed,
most of the new small-molecule and chemical entities of currently available drugs are de-
rived from natural products, which are still widely used as sources of new drugs/leads [1].
Medicinal plants refer to any plants containing substances that can be used for therapeutic
purposes or whose active principles can be used as precursors for the synthesis of new
drugs. Tropical forest medicinal plants have been extensively used by indigenous peoples
to treat several ailments, including cancerous, neurological, infectious, cardiovascular,
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immunological, inflammatory, and related diseases. Thus, the identification of possible
bioactive compounds useful for medicine is of great importance to the pharmaceutical
industry because they can provide new chemical entities or pharmacophores for drug
development [2].
The Virola genus of the Myristicaceae family is found throughout tropical America,
where these species have diverse local ethnobotanical uses [3]. Seed oils of Virola are used
as machinery lubricants or soap ingredients or to make candles with intense light, little
smoke, and fragrant smells. The seeds and arils can also be used to flavor beverages,
such as chocolate drinks, while Virola wood is used for construction and carpentry [3].
Besides their non-medicinal benefits, Virola are perhaps best known for their hallucinogenic
properties, which are often used in South American indigenous cultural practices [4].
Moreover, the reddish exudate of various Virola spp. is applied to treat skin conditions,
alleviate tooth pain, and soothe colic, and as an anti-bleeding substance to treat ulcerating
sores and wounds, as well as hemorrhoids. Additionally, the seed oils have many folk
medicine applications, such as the treatment of asthma, rheumatism, tumors of the joints,
intestinal worms, skin diseases, erysipelas, hemorrhoids, and bad breath [3]. Therefore,
in the last few years, growing research has evaluated the biological effects of species from
the Virola genus, identifying new promising bioactive compounds.
Here, we present an updated and comprehensive review on Virola species, focusing
on their ethnopharmacological uses and phytochemistry. The botany of the Virola genus,
in particular, the distinctive morphological and anatomic characteristics of various Virola
species, are also described in order to support exact species identification, which is rele-
vant for the establishment of unique and unequivocal pharmacological activities, and the
reproducibility of research on the biological activity of their phytochemicals. The final aim
of this review is to support the safe medicinal use of plant extracts and provide guidance
for future research on new molecules with pharmaceutical activity.
2. Botany
2.1. Taxonomy
The Myristicaceae family belongs to the Magnoliopsida class, Magnolianae superorder,
and magnoliid order Magnoliales [5], and contains 21 genera and nearly 500 species of
woody trees, shrubs, and some lianas. The Virola Aubl. genus is the fourth largest, and the
biggest one in America, comprising around 60 species (please see [3] for a comprehensive
taxonomic synopsis). An extensive description of all the Virola spp. is outside the scope of
this review; instead, we summarize the available literature on the species with described
ethnopharmacological uses and biological activity, namely, Virola elongata, Virola peruviana,
Virola venosa, Virola oleifera, Virola sebifera, Virola pavonis, and Virola surinamensis.
2.2. Morphology and Anatomy
The plants of the Virola genus are characterized by distinctive growth forms and fruit.
In particular, they grow as monopodial, orthotropic principal shoots, and plagiotropic lat-
eral branches with distichous phyllotaxy—myristicaceous branching; the fruit’s maturation
is accompanied by dehisce into two valves, displaying a single seed covered by a brightly
colored laciniate aril rich in proteins, lipids, and sugars. These seeds are mainly dispersed
by birds and monkeys [3]. Below, we mention the distinctive morphologic and anatomic
characteristics of the main Virola species.
Virola elongata (synonym Virola cuspidata [6]) has an abaxial leaf surface sparsely
pubescent, trichomes that are concolorous, trichome branches 0.1–0.2 mm long, pedun-
cles of staminate inflorescences 0.07–0.15 cm thick, staminate flowers with the perianths
1.5–1.9 mm long, fruits 1.6–1.9 × 0.9–1.1 cm, a line of dehiscence canaliculate or smooth,
and pericarp 0.5–0.7 mm thick [3].
Virola peruviana comprises trees up to 40 m, with tomentose and glabrescent branches,
that have the following features: oblong leaves 15–35 × 6–11 cm; a cuspid or acuminate
apex; a rounded or subchordinate base; a glabrous upper surface; a lower side with stellate
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trichomes; a sessile, glabrescent base; a glabrous upper surface; a sessile, glabrescent lower
side with secondary stellate trichomes; a middle vein that is flat or slightly emergent
and secondary ones flat or imprinted on the bundle, both emerging on the underside,
secondary veins in 17–30 pairs; slightly brochidodromal camptodromes; inconspicuous
tertiary venation [7].
Virola pavonis consists of trees up to 25 m with stilt roots, and ferruginous-tomentose
or glabrate twigs, with leaves that are oblong–elliptical or obovate–elliptical. They have di-
mensions of 7–21× 1.5–4.5 cm, a subacute or obtusely cuspid apex, an obtuse or attenuated
base, a densely ferruginous-tumultuous upper surface, sessile trichomes, secondary veins
imprinted on the upper surface emerging on the underside in 14–22 pairs in an arched
brochidodrome, and petioles 4–13 mm long [7].
Virola sebifera are trees up to 30 m, sometimes with stilt, tabular roots; twigs that are
tomentose and then puberulent and glabrescent; leaves that are ovate, oblong, elliptical,
or oblong–deltoid; dimensions of 15–47 × 6–15 cm; a sharp or cuspid apex; a cordate
base; a truncated, rounded, or broadly obtuse shape; an upper surface that is glabrous
or sometimes pubescent in the middle vein; an underside that is dense and uniformly
tomentose; persistent or evanescent trichomes that are dendritic, stellate, or irregularly
branched; a middle vein that is slightly emergent and sometimes with two coasts and
secondary ones imprinted on the upper surface, both emerging on the underside; secondary
veins in 10–28 pairs, in a scalloped brochidodrome; and subparallel tertiary venation that
is not very conspicuous [7].
Virola venosa are trees up to 30 m and have ellipsoidal or subglobular fruits, with di-
mensions of 19–22 mm long and 16–18 mm in diameter [8]. They have glabrous or sparse
pubescent leaves on the bottom part and are wedged at the base, with thin venules and
remarkable prominules in both parts, and inflorescences with 2–3 branches [9].
Virola oleifera is a semideciduous tree growing 20–30 m tall; the bole, which is usually
straight and cylindrical, can be free of branches for up to 21 m, and it is 50–90 cm in
diameter [10]. This species has oblong or linear leaves with parallel characteristic margins,
about four times longer than wide, and powdery young lateral branches, which are few
and short, with ovoid–ellipsoid fruits; it is acute or spat at the apex [9].
Virola surinamensis is an evergreen tree growing 25–35 m tall. The straight, cylindrical
bole is buttressed; it can be free of branches for 15–18 m and is 60–90 cm in diameter.
The leaf morphology implies numerous lateral veins, and stellate and sessile trichomes
scattered on the abaxial surface of the leaf blades. This species has sometimes been
identified as Virola nobilis. Both species’ leaves’ sizes and morphology may be similar;
however, they tend to be smaller in V. surinamensis, and it also has inflorescence axes that
are longer and with many more flowers. V. surinamensis is characterized by having a shorter
perianth that is also fleshy to submembranous and smaller fruits that are also ovoid to
subglobose, glabrescent, and with a thin pericarp [11].
2.3. Geographic Distribution
Virola species are extensively distributed in tropical America, being identified from
Mexico to southern Brazil but rarely in El Salvador [3]. Of note, V. surinamensis is the only
species found in the West Indies. The species richness is greater in western Amazonia,
particularly in Brazil (~35 spp.), Colombia (~29 spp.), and Peru (~23 spp.). Central America,
Costa Rica, and Panama have the highest concentration and diversity of Virola species.
They are found mostly in humid forests below 800 m elevation. [3] Specifically, V. elongata
grows in Panama to Brazil; V. sebifera, from Honduras to Brazil; both of them are very
common in South America [3]. On the other hand, the species V. pavonis and V. peruviana
are located in the Peruvian Amazon [12,13]. V. venosa is found in the Colombian Amazon
region [14] and Brazil [15]. V. oleifera grows in the Atlantic Forest [16]; V. sebifera, in Hon-
duras, Nicaragua, Costa Rica, and Panama [3]; and V. surinamensis is distributed from Costa
Rica to the Amazon basin [17].
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3. Ethnopharmacological Uses
Many of the Virola species are exploited for their medicinal properties by local inhabi-
tants to treat and/or manage common human ailments, such as mental instability, infected
wounds, skin infections, colic, and vitiligo [14]. Considering their relevant therapeutic
activity in traditional practice, increasing research has been performed to support Virola
species’ ethnopharmacological uses and identify their mechanisms of action as well as
bioactive compounds (Table 1), ensuring toxicological safety.
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Table 1. Ethnomedicinal uses, biological activity, and bioactive phytochemicals of Virola species.
Species Plant Part Used Type of Extract Traditional Uses
Bioactivity
and Mechanism of Action
(In Vitro and In Vivo Models)
Type of











antioxidant, gastric secretion, and total acidity
reduction
(rodent models of acute and chronic gastric
ulcers)




Antiproliferative in colon adenocarcinoma cells:
cell cycle arrest in G2/M,
anti-mitotic activity
















V. sebifera Leaves Dichloromethane
Cytotoxic and antiproliferative in cancer cells
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Table 1. Cont.
Species Plant Part Used Type of Extract Traditional Uses
Bioactivity
and Mechanism of Action
(In Vitro and In Vivo Models)
Type of
Compound Compound Identified Ref.
















antioxidant and antiapoptotic in renal
glomerular and tubular cells
(contrast-induced nephropathy mouse model)















inhibition of gastric lesions
(ethanol/HCl, indomethacin, stress, and pylorus















(acetic acid-induced abdominal writhing test and
formalin test in mice)
Anti-inflammatory
(croton oil-induced ear oedema test in mice)
Neolignans Grandisin
Hexane Anti-schistosomal and anti-leishmanial activity(in vitro tests) Neolignans Surinamensin [27,28]
Plantlet leaves Essential oil Malaria Antimalarial(in vitro test) Sesquiterpenes Nerolidol [29]





Inhibition of CYP2C9 and CYP3A4/5 Neolignans Grandisin [31]
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V. elongata stem bark hydroethanolic extract is used for the treatment of stomach pain,
indigestion, and gastric ulcers. This extract attenuates gastric ulceration by enhancing
gastroprotection through its antioxidant properties and ability to significantly reduce
gastric secretion and acidity in mouse and rat models of acute (acidified ethanol, piroxicam,
and restraint-in-water stress) and chronic (acetic acid) gastric ulcers at doses of 100, 300,
and 900 mg/kg p.o. (per os, orally) [6]. The aqueous infusion or the hydroethanolic
macerate of the stem bark of V. elongata is also used in Brazilian and Ecuadorian indigenous
folk medicine for the treatment of venereal diseases, abnormal vaginal secretions, infections,
and cancer and for blood purification and wound healing [6]. Furthermore, V. elongata has
shown tranquilizing effects and locomotor central nervous system depression, being used
as a hallucinogenic drug because of its alkaloids [32].
In popular medicine, V. oleifera is used to accelerate wound recovery and to treat pain
and inflammatory conditions [9]. The oil extracted from the seeds of V. oleifera is popularly
used for rheumatic pain, bronchial asthma, tumors in the joints, intestinal worms, halitosis,
hemorrhoids, and skin diseases [9]. Validating its traditional use, V. oleifera resin (Figure 1)
demonstrated gastroprotective effects (reduced gastric mucosal damage) in an ethanol/HCl
and indomethacin ulcer-induction mouse model at 10 and 100 mg/kg when administered
orally 30 min before gastric lesion induction, comparable to the reference control lanso-
prazole (3 mg/kg) [16]. Moreover, the chronic administration of antioxidant resin from
V. oleifera (50 mg/kg administered orally) also attenuates atherogenesis in the atheroscle-
rotic LDLr−/− mouse model, through a decrease in vascular lipid deposition, the protection
of the vascular endothelium and smooth muscle cells against peroxide-induced cytotox-
icity, and the reduction of LPS-induced nitric oxide production in macrophages. Thus,
V. oleifera resin’s anti-atherogenic activity might be mediated by systemic as well as local
antioxidant and anti-inflammatory mechanisms [22]. Furthermore, the evaluation of the
V. oleifera resin (300 mg/kg) in mice has suggested it to be a potential therapeutic solution
for radiocontrast-induced nephropathy, due to its antioxidant and antiapoptotic effects and
its ability to preserve kidney function by reducing renal dysfunction and morphological
tubular injury [33]. Our current work also supports the ethnopharmacological use of
V. oleifera in musculoskeletal malignancies, namely, multiple myeloma, and evidenced its
potential as an adjuvant therapy to optimize dexamethasone’s pharmacologic effects and
overcome cell drug resistance; nevertheless, herb–drug interactions with the proteasome
inhibitor bortezomib could limit its clinical use (unpublished data).
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Figure 1. Virola oleifera in Espirito Santo, Brazil. he resin as collected from 0.5 cm-deep incisions in
the tree trunk, as demonstra ed in (A), and transferr d into an amber glass vial (B). The fluid exudate
was dried at 40 ◦C (C) and grou . Afterwards, the resin was sheltered from light at 4 ◦C un il used
as shown in (D). Previous chemical characterization by our research group revealed a high content of
polyphenols, the main compounds demonstrated in (E) [16,33].
V. surinamensis is widely used by the riverside inhabitants of the floodplain forest of
the Mazagão River in the Brazilian Amazon to treat different disorders [34]. In particular,
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V. surinamensis seed oil is used topically for inflammatory skin conditions and as a pre-
ventive for microbial infections during wound healing. The oil is also used as a repellent.
Leaf and bark decoctions are used as oral preparations for the treatment of inflammation
in the digestive, urinary, and reproductive systems. Bark and fruit decoctions are used for
intestinal infections, while exudate poultices are applied topically for furunculosis [34].
The resin obtained by cuts in the stem bark is also a reputed folk remedy in its natural form
for the treatment of ulcers, gastritis, inflammation, cancer, erysipelas, colic, and dyspep-
sia [25,26]. Accordingly, the ethanolic extract (EE) of V. surinamensis resin has demonstrated
preventive activity in rodent models of gastric mucosal disease [26]. Pre-treatment with
the V. surinamensis resin EE (500mg/kg, p.o.) significantly inhibits mucosal injury (95%
inhibition) in a gastric hemorrhagic ulcerative lesion model induced by an acidified ethanol
solution. At the same dose, this extract also significantly reduced the formation of gastric
lesions induced by indomethacin (39%), stress (45%), and pylorus ligature (31%) in mice,
when compared to control animals. Interestingly, a comparison between the oral and
intraduodenal administration of the V. surinamensis resin extract indicated therapeutic
activity by local action, since no changes in gastric biochemical parameters (pH or total
acid) were observed after intraduodenal administration [26]. Being the main constituent
of V. surinamensis resin EE, epicatechin was suggested to be among the active principles
responsible for the plant’s antiulcer activity [26]. An ethanolic extract of V. surinamensis
stem bark was prepared and dried, and a 10% (w/v) solution diluted in dimethylsulfoxide
was further tested for antimicrobial activity by measuring the diameter of the growth
inhibition zone [25]. The extract exhibited antibacterial activity, particularly against Gram-
negative microorganisms, thus providing preliminary scientific validation of its traditional
medicinal uses. The phytoconstituents responsible for the antibacterial activity have not
yet been identified, but it may be attributable to the presence of high concentrations of
tannins, phenolic compounds, or catechin [25].
Furthermore, V. pavonis root and stem bark decoction is also known to be used for the
treatment of skin infections and mucal mycosis [13].
4. Phytochemistry
Along with the determination of Virola spp.’s bioactivity, the characterization of
the chemical composition, both compound identification and quantification, has also
been performed. Furthermore, some studies have discussed the contribution of isolated
compounds to the whole extract’s activity.
The chemical characterization of a stem bark hydroethanolic extract of Virola elongata
revealed a content of 14.6% phenolic compounds (around 50% are flavonoids), among which
are known antiulcer phenolic compounds, such as gallic acid, catechin, and rutin [6]. Quinic
acid, 3,3′,4-trihydroxystilbene, juruenolid D, one catechin dimer, one C-glycosyl flavonoid,
one polyketide, and two neolignans were also identified as major components of the stem
bark hydroethanolic extract [6]. V. elongata (also known as V. cuspidata) contains the nat-
ural resveratrol analog (Z)-3,5,4′-trimethoxystilbene, which completely abrogated Caco-2
cell growth at 0.4 µM, while an 80% cell growth inhibition was observed at 0.3 µM (IC50:
0.25 µM). Analysis of its mechanisms of action indicated a blockage of the G2/M phase
and the inhibition of tubulin’s polymerization, which plays a key role in neoplastic disease
development [18]. Of note, under the same conditions, the (E)-3,5,4′-trihydroxystilbene
(resveratrol) also showed a 70% inhibition of Caco-2 cell growth but at a higher concentration
of 25 µM, which means that (Z)-3,5,4′-trihydroxystilbene is 100-fold more active than resver-
atrol [18]. The β-carbolines 6-methoxyharmalan and 6-methoxyharman, which have been
suggested to possess some psychoactive effects, have also been isolated from V. elongata [19].
The isolation of 5-methoxy-N,N-dimethyltryptamine as well as the identification of
N,N-dimethyltryptamine and 5-methoxytryptamine in V. peruviana has shown that the
compounds may have hallucinogenic effects [12].
The bioassay-guided fractionation of a V. sebifera dichloromethane leaf extract iso-
lated and elucidated the structure of polyketide 3,5-dihydro-2-(1′-oxo-3′-hexadecenil)-2-
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cyclohexen-1-one, which showed cytotoxic activity selective against the human tumor cell
lines OVCAR03 (ovarian) and NCI-ADR (with a multidrug-resistance phenotype), in a
dose-dependent way (IC50: 2–4 µg/mL) [20,21]. Additionally, the antiproliferative proper-
ties of V. sebifera (4′Z)1-hexadec-4′-enoyl-2,6-dihydroxybenzene [21] and polyketides from
the leaves were reported, presenting moderate activity in all the cancer cell lines evaluated
(IC50: 41–176 µg/mL) [20]. Additionally, two lignans were described in V. sebifera, rel-(8R,
8′R)—3 4:3′, 4′-bis-(methylendioxy)-7.7′-dioxo-lignan and (7′R, (‘S,8S)-2′-hydroxy-3,4:4,5′-
bis-(methylenedioxy) -7oxo-2,7′-cyclolignan [35], whose antioxidant activity was further
demonstrated, similarly to that for other natural aryltetralone lignans [36].
V. venosa’s blooms, fruits, and seeds contain flavonoids, lignans, arylalkanones,
and sitosterol, while alkaloids and stilbenes are present in the leaves and roots [37]. Ary-
lalkanones or acylarylrecorcinols have been found not only in V. venosa (both fruits and
bark) but also in V. elongata, V. surinamensis, and V. sebifera [14]. Research investigating the
α-glucosidase inhibitory activity of V. venosa and its bioactive compounds revealed that the
methanolic extracts of the bark and leaf had a high content of phenolic compounds, demon-
strating a high activity in antioxidant and α-glucosidase-inhibitory tests. These results
are therapeutically relevant since inhibitors of α-glucosidase are potential compounds for
the treatment of diabetes because they reduce diet-induced hyperglycemia by inhibiting
this intestinal enzyme [15]. Furthermore, the activity-guided fractionation of V venosa
methanolic bark and leaf extracts showed the presence of phenolic acids (ferulic acid, gallic
acid, and ρ-coumaric acid) and flavonoids (quercetin, quercetrin, kaempferol, and cate-
chin), and identified ferulic acid as the main bioactive compound for the antioxidant and
α-glucosidase-inhibitory activities [15].
The renoprotective activity of V. oleifera resin may be attributable, at least in part, to the
presence of antioxidant species, such as ferulic acid, gallic acid, and quercetin, previously
identified by our group [33]. Moreover, we also described that the gastroprotective effect
of this extract could be related to the content of polyphenols (~82%), namely, tannins
(67.66 g/100 g of resin), phenolic acids, and flavonoids (48.257 ± 28.27 mg quercetin
equivalent/100 g of resin), particularly epicatechin and eriodictyol [16]. V. oleifera leaf
methanolic extracts have shown promising results as an analgesic treatment, which could
be related to the oleiferin-C and flavonoid (quercitrin and astilbin) content [23]. The ad-
ministration of V. oleifera leaf methanolic extract (10 mg/kg i.p.) inhibited acetic acid-
induced abdominal constriction in mice similarly to aspirin or paracetamol [23]. Notably,
oleiferin-C dose-dependently inhibited abdominal constriction by 76% at 29.2 µmol/kg
(ID50: 17.2 µmol/kg), being 7.5-fold more active than aspirin (ID50: 125 µmol/kg) or
paracetamol (ID50: 133 µmol/kg). In this study, the compounds quercitrin (quercetin-3-
O-rhamnoside) and astilbin (taxifolin-3-O-rhamnoside) were also identified in the ethyl
acetate fraction in a 2:1 ratio (quercitrin: astilbin), causing a reduction of 63% in abdominal
muscle constriction. Since astilbin is inactive as an analgesic in mice, the effects of the
quercitrin:astilbin mixture are likely due to quercitrin itself or to a potentiating synergistic
effect between the two compounds [23].
Surinamensin is a natural neolignan isolated from the leaves of V. surinamensis,
whose activity against Leishmania donovani amastigotes and promastigotes was tested
in vitro based on its anti-schistosomal activity [27]. Steroids, lignans, flavonoids, and polyke-
tides were also isolated from V. surinamensis [27]. The results revealed that surinamensin
is active against L. donovani promastigotes but showed no selective toxicity when tested
against the amastigotes in the mouse peritoneal macrophage model [28]. Besides, the 8.O.4′-
neolignan 3,4,5-trimethoxy-8[3′,5′-dimethoxy-4′-propenylphenoxy]-phenylpropane was
isolated from Virola pavonis, and it showed in vitro anti-L. donovani promastigote activity at
100 µM in an assay using extracellular promastigotes [28].
The neolignan grandisin was identified in V. surinamensis as well as in several Brazilian
plant species used in popular medicine for the treatment of colic, inflammation, rheumatism,
dyspepsia, and liver dysfunction. The antinociceptive and anti-inflammatory properties
of grandisin have been investigated [24]. Treatment with grandisin (1, 3, and 10 mg/kg)
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dose-dependently reduced the number of acetic acid-induced abdominal writhes in mice,
similarly to indomethacin at the highest dose used. Furthermore, the data indicated that
the antinociceptive activity of grandisin is not dependent on motor incoordination or
sedation due to the depressant effect in the CNS. The further evaluation of grandisin’s
antinociceptive and anti-inflammatory activities in rodent models using the formalin
test (a 60.5% reduction in paw licking time only in the inflammatory phase response),
the croton oil-induced ear edema test (a 36.4% edema reduction at 10 mg/kg), and the
carrageenan-induced peritonitis test (no effect at the concentrations tested) suggested that
the mechanism of action of grandisin is not associated with the inhibition of events in
the late stage of the inflammatory process, in which chemotaxis and cell migration occur.
Instead, grandisin is hypothesized to reduce prostaglandin formation and/or activity
through the inhibition of cyclooxygenase activity or prostaglandin receptor antagonist
action. These results support the traditional use of grandisin-rich plants, such as V. suri-
namensis, in the treatment of symptoms caused by an inflammatory process such as pain
and edema [24]. Grandisin was also identified as a potential drug candidate due to its
antitumor and trypanocidal activities. Furthermore, grandisin is a competitive inhibitor of
CYP2C9 and a competitive and mechanism-based inhibitor of CYP3A4/5 [31].
The essential oil obtained from adult and plantlet leaves of V. surinamensis has also been
analyzed by GC–MS, and 11 monoterpenes, 11 sesquiterpenes, and three phenylpropanoids
were identified. The plantlet essential oil caused 100% growth inhibition after 48 h in the
development of the young trophozoite to the schizont stage, and the sesquiterpene nerolidol
was identified as one of the active constituents, indicating a potential antimalarial use [29].
Dichioromethane extracts from V. surinamensis twigs showed in vitro trypanosomicidal
activity against the trypomastigote form of Trypanosoma cruzi [30]. Costa et al. suggested
that V. surinamensis’s antimicrobial activity is due to its tannin content [25].
5. Conclusions
Phytotherapy and the use of medicinal plants are traditionally part of the popular
knowledge of different populations, users, and practitioners. The World Health Organiza-
tion estimated that 80% of the developing countries’ population still relies on traditional
medicines, medicinal plants being the most used, for its primary health care; they consti-
tute an effective therapeutic form for the lower-income community. As evidenced in this
review, Virola genus species are broadly used by local American inhabitants due to their
beneficial effects on digestive conditions and rheumatic diseases, as well as inflammatory
and infectious illnesses. In the last few years, several efforts have been made to validate
the traditional uses of Virola spp. in human health and to identify bioactive phytochem-
icals. Several phenolic compounds, alkaloids, sesquiterpenes, lignans, and neolignans
have been identified as antioxidant, anti-inflammatory, antinociceptive, and antimicrobial
compounds. Of note, most of the studies were conducted on in vivo models, thus con-
firming their efficacy, therapeutic doses, and bioavailability. In this context, Virola genus
species are evidenced as potential sources of therapeutic leads, offering novel opportunities
in the search for new drugs. However, further basic and clinical research is needed to
clarify and confirm the biological actions of Virola species and their bioactive molecules,
minimizing the possible side and toxicological effects. Finally, studies on the potential
herb–drug interactions as well as structure–activity relationships will be of relevance in the
development of new pharmaceutics derived from Virola species phytochemicals.
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